Metabolic Effects of Paricalcitol

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Kidney Disease

In brief

The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).

Key facts

Study ID

NCT01003275

Run by

University of Washington

People needed

22

Starts

2009-10-01

Expected to finish

2011-11-01

Last updated by the study team

2014-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Estimated glomerular filtration rate of 15-59 mL/min/1.73m2
• Fasting glucose 100-125 mg/dL
• 18 years and older

You may not qualify if…

• Diagnosed with diabetes mellitus
• Use of diabetes medications (insulin or oral hypoglycemics)
• Prior dialysis or transplantation
• Planning to leave the area within 6 months
• Participation in another clinical trial within 30 days
• Treatment with paricalcitol, calcitriol, or corticosteroids in the preceding 8 weeks
• Serum calcium more than 10.2 mg/dL
• Pregnancy or breast-feeding
• Change in dose (within 8 weeks) of Fibrates, Niacin, ACE inhibitors, Angiotensin receptor blockers, Thiazide diuretics, Beta-blockers, Cholecalciferol or Ergocalciferol
• Incontinent of urine
• Cancer (other than skin cancer) within 5 years
• Tuberculosis
• Sarcoidosis

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.